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G-Force PD: a global initiative in coordinating stem cell-based
dopamine treatments for Parkinson’s disease
Roger A Barker1, Lorenz Studer2, Elena Cattaneo3, Jun Takahashi4 and G-Force PD consortium5
Translating new cell-based therapies to the clinic for patients with neurodegenerative disorders is complex. It involves pre-clinical
testing of the cellular product and discussions with several regulatory agencies, as well as ethical debates. In an attempt to support
efforts around the world, we set up a global consortium that brings together the major funded teams working on developing a
stem cell-derived neural transplantation therapy for Parkinson’s disease (PD). This consortium, G-Force PD, involves teams from
Europe, USA, and Japan, and has already met on two occasions to discuss common problems, solutions, and the roadmap to the
clinic. In this short review, we lay out the brief history and rationale for this initiative and discuss some of the issues that arose in our
most recent meeting (May 2015) as we consider undertaking first-in-human clinical trials with stem cell-derived neurons for PD.
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INTRODUCTION
There are no curative therapies for chronic neurodegenerative
conditions. These conditions include Alzheimer’s disease,
Parkinson’s disease (PD), Huntington’s disease (HD), FrontoTem-
poral Dementia, and amyotrophic lateral sclerosis. Of these, PD is
the most amenable to therapy given that part of its pathology is
defined by the loss of nigral dopaminergic neurons, which means
that dopaminergic therapies can be employed with great success
at least in the early stages of the condition.1 Pharmacological
dopamine replacement therapy, which began over 50 years ago,
shows that dopamine replacement is transformative, albeit not
curative, for PD patients. Furthermore, when given in the form of
oral therapies, it leads to non-physiological stimulation of
dopamine receptors. This in turn leads to the common, and
potentially severe, side effects including L-DOPA-induced
dyskinesias (LIDs), as well as psychiatric and cognitive problems.
Such complications have been addressed by many new therapies
including deep brain stimulation (DBS) and continuous delivery
of dopaminergic agents (e.g., Apomorphine and DuoDopa
infusions).2
Despite these therapeutic triumphs, the pathogenic process
underlying PD continues. After 10–15 years, most patients exhibit
numerous motor complications and a range of non-motor deficits.
Consequently, there is a desperate need for effective disease-
modifying therapies, but until such a therapy is available; an
alternative approach is to try to repair the dopaminergic
nigrostriatal system. One such approach to brain repair involves
grafting dopaminergic neurons to replace those lost to the
original disease process.3
Neural grafting for PD has a long history going back to the late
1970s, when it was shown that immature dopamine neurons
could restore dopamine levels and mitigate behavioral deficits in
animal models of PD. Dopaminergic neurons derived from the
fetal ventral mesencephalon (fVM) of the appropriate develop-
mental age (embryonic day 13–14) survived grafting in the adult
rodent striatum, extended axons into the transplanted brain, and
formed synapses with host neurons. In addition the grafts restored
tissue levels and release of dopamine in the striatum, which was
coupled to normalization of drug-induced and spontaneous
behavioral deficits.3 This was reproduced in many laboratories
worldwide and in 1987 led to the first clinical trials in patients that
ran for about another 13 years.4 In these studies, patients typically
received intrastriatal grafts of human fVMs derived from 1 to 8
aborted foetuses (aged 7–9 weeks post conception) implanted
into each side of the brain. The patients were often in moderate to
advanced stages of PD with already manifest LIDs.
The original clinical studies were open label and showed that
some patients in receipt of such transplants did well for many
years and could even reduce or discontinue their anti-PD
medication. In the most successful cases the striatal F-DOPA
uptake, monitored by positron emission tomography (PET),
returned to normal levels 3–5 years after surgery.5 However, not
all patients improved and the optimal patient population and
delivery approach using this fetal tissue was still not fully resolved
when two double-blind placebo controlled studies were
undertaken in the USA, supported by the National Institutes of
Health. These clinical studies, in contrast to the open label studies,
found no significant benefit from the grafts. In addition, many of
the patients developed a complication from the procedure,
namely graft-induced dyskinesias.6,7 The publication of these
results at the beginning of this century led to a moratorium on this
approach, especially as newer more easily applied therapies such
as DBS became available.
In order to try to better understand these disparate findings, an
international working group was set up in 2006 supported by
Parkinson’s UK, to which all those involved in such trials were
invited. These meetings over the ensuing 2 years sought to
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analyze the data to see whether lessons could be learnt from the
trials that had already taken place and then to use those data to
inform the future development of these therapies in the clinic.
This collaborative approach enabled the community to agree that
the patients who derived most benefit from these grafts were
generally younger, earlier in their disease course and in receipt of
transplants derived from at least three human fVMs. This
information was then used to design a new trial looking at this
approach in PD, TRANSEURO, which was funded by the European
Union (EU) in 2009 and led to the first transplants being
performed in 2015.
This whole process taught us two main things: (i) working as a
collaborative group enabled conflicting views to be discussed and
debated, which ultimately improved the rationale and approach
adopted in taking such therapies forward; and (ii) the regulatory
landscape when using such cells is complex and often ill-defined,
and working together as a group with the relevant authorities
sped up and informed the whole process. This collaborative
approach with regards to fetal grafting led to the idea that those
working with multiple types of stem cell-derived dopaminergic
cell therapies for PD may also benefit from working together as a
consortium.8
G-FORCE PD—ITS ORIGINS
The teams that originally sought to work together to develop this
new consortium were drawn from those groups who were in
receipt of significant funding for such programs of work
(see below and Figure 1).
● TRANSEURO—a Framework Program 7 (FP7) EU funded
consortium that seeks to reintroduce fetal VM allografts into
clinical trials with patients with PD (http://www.transeuro.org.
uk/);
● NEUROSTEMCELLREPAIR (NSCR)—an FP7 EU funded consortium
that seeks, as one of its main goals, to develop good
manufacturing practice (GMP) grade dopaminergic neurons
from stem cell sources for eventual use in patients with PD
(http://www.neurostemcellrepair.org/; http://www.crm.ed.ac.uk/
research/group/mechanisms-neurodegeneration);
● NYSTEM have awarded a contract to L.S., Viviane Tabar and
colleagues at Memorial Sloan Kettering (MSKCC) in New York to
develop a human embryonic stem cell-derived clinical grade
dopaminergic midbrain neuron for use in clinical trials in PD
(https://www.mskcc.org/research-areas/programs-centers/new-
york-state-stem-cell-science-consortia);
● CiRA—a Japanese research centre that is funded to do many
types of regenerative cell-based therapies. In particular, Jun
Takahashi is funded to develop a clinical grade dopaminergic
cell therapy from autologous-induced pluripotent stem cells
(iPS cells) taken from the PD patients (https://www.cira.kyoto-u.
ac.jp/e/);
● The California Institute for Regenerative Medicine (CIRM), given
their involvement in funding regenerative cell-based therapies
in California, even though they are not currently funding a
major ongoing clinical PD programs in this area.
Other organizations/groups that also came to the meetings
included:
● Other parties with a vested interest in this field including, e.g.,
representatives of the two major US PD-related charities—the
Michael J. Fox Foundation for Parkinson's Research (MJFF) and
the Parkinson's Disease Foundation (PDF);
● A Medical Research Council (MRC) funded project led by Tilo
Kunath in the UK that seeks to apply established dopaminergic
differentiation protocols to existing UK derived human GMP
grade Embryonic Stem (ES) cell lines.
The first of these meetings took place in London in May 2014
with a second meeting in New York in 2015. Both meetings lasted
1.5 days and involved each group presenting their own program
of work and how they were aiming to take this therapy to clinic.
These presentations were followed by discussions on the
Figure 1. The geographical distribution of the relevant parties involved in G-Force PD. 1=NYSTEM consortium involving centers in New York
and Chicago; 2=CIRM; 3= Lund University who are part of TRANSEURO and NEUROSTEMCELLREPAIR; 4=University of Milan that co-ordinates
the NEUROSTEMCELLREPAIR consortium; 5=A number of UK sites including the Universities of Cambridge, Cardiff, and London who are
involved in NEUROSTEMCELLREPAIR and TRANSEURO; 6=CiRA.
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problems and challenges that lay ahead in taking this therapy to
patients and a roadmap to the first clinical trial (http://www.
gforce-pd.com/). A similar meeting is in the planning stages to
take place in Chicago in 2016. The funding for each meeting was
met from funds within their consortia, as well as support from the
Parkinson’s UK in the first meeting in London and the PDF and
Weill Cornell for the meeting in New York.
G-FORCE PD—THE CHALLENGES
The main challenges that were addressed at each meeting were:
● The pre-clinical data defining all the requirements of a stem
cell-derived dopaminergic neuron making it sufficiently likely to
be efficacious and safe so it can be considered for use in a
clinical trial. This has been the subject of a number of recent
reviews.9,10 In essence, before any stem cell-derived dopami-
nergic neuron can be considered suitable for patients with PD,
it needs to express a number of basic characteristics. This not
only embraces issues around the stem cell source (e.g., which
ES cell line, genetic stability, minimal or no risk of zoonoses) but
also the identity and stability of the dopaminergic neurons
derived from the stem cell line. To date, there is no clear
regulatory path in either Europe or in the USA as those that
exist were created before pluripotent stem cell therapies were
developed. Despite this ambiguous regulatory landscape, a
number of groups have entered clinical trials using pluripotent
stem cell-derived products in USA, UK, and Japan. In Europe, it
is preferred that the starting material (i.e., ES cell line) is created
using the highest standard of material available, specifically that
the original line be derived under GMP conditions, with appro-
priate consent and processed throughout in xeno-free condi-
tions. However, there are some trials already underway in which
the starting materials do not reach these standards. In USA, a
number of trials have been initiated in which the starting material
is considered ‘research grade’ and a xenogeneic product. Of
greater concern in USA is the lack of adequate testing for
transmissible spongiform encephalopathies—rendering all cell
lines derived from UK donors non-compliant with US Food and
Drug Administration (FDA) donor eligibility requirements (Title
21 Code of Federal Regulations, part 1271). As such, it is likely
that the ES cell lines initially used for clinical trials in USA and
Europe may be different, while in Japan the focus is on using
patients' own cells to make autologous iPS cell lines. At the time
of writing, though, there appears to be a shift in emphasis away
from patient specific to previously banked Human Leukocyte
Antigen-typed iPS cell lines in this country, due to complica-
tions in patient-by-patient banking.
The cell production processes in the pre-clinical work can now
yield differentiated cells that express an array of relevant
markers for midbrain dopaminergic neurons with fiber
outgrowth.11,12 However, it is still debated what markers these
cells should express and at what levels. Nevertheless, in all cases
the dopaminergic neurons produced by the G-Force PD
partners appear to display the critical morphological, neuro-
chemical, and transcriptional markers of appropriate cells,
with pacemaker potentials, dopamine release, and functional
integration and effects in animal models of PD without tumor
formation or overgrowth. However, in all cases questions still
arise as to whether the manufacturing and differentiation
protocols for generating these cells have been optimized in
each center (or at least developed to a level to support a clinical
trial). This is critical because it is only at this point that the
process can be locked down and moved to GMP.
● The necessary GMP manufacturing processes to take the cell to
a clinical trial. Entry into a phase 1 trial does not necessarily
require all reagents to be of GMP grade, but they must be
properly sourced and tested. This is often thought to be
relatively straightforward, but represents a major hurdle as the
relevant reagents are in some cases extremely hard, if not
impossible, to find. If they can be sourced, the cost is
often much greater than equivalent research grade material.
Furthermore, the change from a research grade reagent to one
of an equivalent GMP grade can affect the whole differentiation
outcome. Thus, many experiments, including validations in vivo,
need to be done to verify that the original lab-based protocols
still work under GMP conditions. All groups are now tackling
this issue and sharing reagents where possible, also in part to
disperse cost. Assay development (for quality and batch
control) is also critical in demonstrating a robust and
reproducible process and product. Like the conversion to
GMP compliant protocols, it is often underestimated and
requires extensive effort and cost.
● Issues concerning cell sorting and cryopreservation of the final
product. Cell sorting has the advantage that it can select out
cells that are not wanted (non-dopaminergic neurons or neural
progenitors) and/or positively select for the wanted cells. All of
this runs the risk that many cells are lost in the process and
having a pure dopaminergic neuronal population as a final cell
product, without some supportive glial cells, may not be ideal.
Cell sorting also introduces an additional complication into any
manufacturing process. In the case of using positive sorting,
one must consider the quality of the antibody used, as it may
be carried along with the cell product, at least transiently. GMP
grade antibodies are also expensive to make and take a
considerable time to be generated. Cryopreservation of cells
seems to require dimethyl sulfoxide (DMSO), and while low
levels can be tolerated in cells delivered peripherally to patients
for other medical reasons, there is less information about how
well residual levels of DMSO may be tolerated following
injection of the cells into the brain.
● Regulatory processes required in taking any new stem
cell-based trial into the clinic for PD. There are many unknowns
in taking a new therapy to clinic that are almost impossible to
answer in the laboratory, and these include the long term
survival of the cells (over years) and their stability, as well as
their immunogenicity in the human brain. Thus, early discus-
sions with the relevant regulatory authorities have already
begun for many in the consortium, to see what safety studies
will be required, including the need for cell sorting (see above),
as well as non-human primate grafting experiments. This may
vary between countries with the FDA differing from the
European Medicine Agency and Japanese authorities in what
they would want to see in the final product submission for a
clinical trial.
● The structure of a Phase I clinical trial using this type of cell
product. As this will be a first-in-human study, a balance will
need to be struck between grafting patients with late stage
disease, who may have exhausted other options, against those
most likely to benefit from the therapy, who may be younger
and have less severe symptoms.13 Although an argument can
be made that the ideal patient population was defined in the
ongoing TRANSEURO study with human fVM tissue, it is more
likely that the upcoming phase 1 studies will involve patients
with relatively advanced disease who experience motor
fluctuations, but nonetheless remain free of major non-motor
problems. This was the case for the patients selected for the
initial human fVM grafts and clearly gave early indications on
the magnitude of effects that such grafts could exert. These first
trials will focus on tolerability and feasibility endpoints,
including magnetic resonance imaging screening to monitor
for graft overgrowth. In addition, signs of efficacy will clearly be
examined both clinically and through imaging using PET
ligands for the dopaminergic system. The exact clinical trial
designs for the US and the European groups are currently being
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discussed, but may be modified depending on what the
regulatory authorities' request, and this extends to the dose of
cells that will be grafted. In the Japanese studies, the patients
will need to be identified early on if the decision is made to use
autologous iPS cells as the source of the dopaminergic neurons
for grafting.14
● Developing bioethical underpinnings for a first-in-human cell
transplant trial. Trials of this nature present a variety of ethical
challenges that require careful attention. Among such chal-
lenges are decisions about: how much and what type of
evidence is required before proceeding to experimentation in
human beings; how to ensure that risks to participants are
minimized while potential benefits to them and society are
maximized; how to design an informed consent process that
enables participants’ to make truly autonomous decisions; and
how to limit and manage conflicts of interests. These ethical
challenges are not unique to stem cell transplantation trials.
However, the publicity that surrounds such research, the great
promise that these potential treatments present, the significant
uncertainty about risks and potential benefits, and the
devastating consequences that an initial failed trial could have
for the stem cell field, all call for particular care in addressing
these ethical challenges.
● Involving the broader community. PD-related charities and
foundations already have a valuable role in enhancing the role
of the public in developing clinical research enterprises. In
addition to providing educational resources on research efforts,
some support development of patient research advocates. Such
engaged individuals provide a direct link to the PD community,
support advocacy efforts, and may aid in shaping aspects of
clinical trials, for example developing information materials that
will support trial participants from the informed consent
process and beyond.
● Ability to encourage others to be a part of this or similar
consortia. While this meeting sought to bring together many of
the relevant groups in this field, there are other privately
funded enterprises seeking to do similar work. Although it may
not be possible for all to participate in such meetings at this
time, given the confidential nature of their work, it is hoped that
they will seek to follow similar approaches to those we are
collectively adopting to help prevent a premature translation to
the clinic.
● The commercialization of the cell product and its ultimate
position in the clinic. While this remains some way off, it is
important to recognize that academic institutions and their
principal investigators can only develop these therapies
so far. Larger phase 2 and 3 studies will be prohibitively
expensive and will require a major investment from industry.
With this will come issues of intellectual property (IP), the
ownership of the cell product and a loss of control of the
development of that product in terms of trial design, disease
indication and marketing. Thus, although there is little one can
do to change this process, securing good IP early on, and
remaining active in the appropriate promotion of the cell
product by those involved in its early development will be vital
if these treatments are to be competitive and useful to
patients.
CONCLUSION
This second meeting of G-Force PD served to once more highlight
the value of sharing knowledge and expertize around a common
goal relating to an exciting, but unproven, experimental cell
therapy for PD. It is hoped that others working in similar fields
(e.g., gene therapies for neurodegenerative disorders; cell therapy
for HD and so on) may also wish to adopt such an approach, and
by so doing help prevent premature clinical trials, while also
ensuring that the work moves forward as quickly and efficiently as
possible. By doing so, it should reach its ultimate goal at a time
when all those best qualified to assess it, agree that this is the
case, and only at such a time.
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